Although immune checkpoint activation is associated with bad prognosis, such tumors are also more likely to respond to immune checkpoint inhibitors.13 As it has been reported that low mutation rates in various types of human cancer, including bladder carcinomas, are associated with diminished responsiveness to such inhibitors,13,36,37 we examined the TCGA data on bladder cancer to determine the frequency of genetic alterations in tumors expressing high or low levels of FGF-2. The gene discussed is FGF2; the disease is cancer.